Opinion|Videos|June 20, 2024
Adolescent Acne Management: Strategic Approaches and Leveraging Clascoterone Cream
Author(s)Hilary Baldwin, MD
Hilary Baldwin, MD, presents a case study of a 17-year-old high school student with moderate acne vulgaris on her face and back, which caused significant emotional distress and lowered self-esteem, and discusses the patient's treatment journey and the resolution achieved.
Advertisement
- What is your impression of this case? What challenges does it present?
- How might the patient’s use of makeup to cover up her acne contribute to her condition?
- What recommendations would you provide regarding makeup use for acne-prone individuals?
- What additional information would you want to gather from this patient regarding her acne history, previous treatments, and lifestyle factors before determining the next steps in her treatment plan?
- As a treatment-naïve patient, how would you treat her?
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5